Benitec Biopharma Inc. (NASDAQ:BNTC) shares, rose in value on Friday, 08/05/22, with the stock price down by -7.48% to the previous day’s close as strong demand from buyers drove the stock to $0.79.
Actively observing the price movement in the last trading, the stock closed the session at $0.85, falling within a range of $0.7341 and $0.8825. The value of beta (5-year monthly) was 1.41. Referring to stock’s 52-week performance, its high was $4.78, and the low was $0.67. On the whole, BNTC has fluctuated by -29.42% over the past month.
With the market capitalization of Benitec Biopharma Inc. currently standing at about $6.33 million, investors are eagerly awaiting this quarter’s results, scheduled for Nov 15, 2021. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.28, which is expected to increase to -$0.29 for fiscal year -$1.89 and then to about -$0.87 by fiscal year 2023.
Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $100k, representing an increase of 69.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that BNTC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BNTC currently trading nearly -19.05% and -19.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.47, while the 7-day volatility ratio is showing 14.69% which for the 30-day chart, stands at 10.51%. Furthermore, Benitec Biopharma Inc. (BNTC)’s beta value is 1.26, and its average true range (ATR) is 0.13.
Data on historical trading for Benitec Biopharma Inc. (NASDAQ:BNTC) indicates that the trading volumes over the past 10 days have averaged 90580.0 and over the past 3 months, they’ve averaged 2.22 million. According to company’s latest data on outstanding shares, there are 8.17 million shares outstanding.
Nearly 9.92% of Benitec Biopharma Inc.’s shares belong to company insiders and institutional investors own 18.70% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.1 million shares as on Jul 14, 2022, resulting in a short ratio of 0.02. According to the data, the short interest in Benitec Biopharma Inc. (BNTC) stood at 1.26% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 9860.0. The stock has fallen by -69.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BNTC stock heading into the next quarter.